We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The renowned medical cannabis company posted earnings per share (EPS) of 4 cents in the last reported quarter, which surpassed the Zacks Consensus Estimate by 130.77%. The company’s earnings topped estimates in each of the trailing four quarters, the average surprise being 176.92%.
ACB’s Fiscal Q2 Estimates
For the fiscal second quarter, the Zacks Consensus Estimate for Aurora Cannabis’revenues is pegged at $52.5 million, indicating a 20.1% decrease from the year-ago reported figure.
The Zacks Consensus Estimate for the company’s fiscal second-quarter stands at a loss of 3 cents, in contrast to an EPS of 9 cents in the prior-year quarter. The estimate has remained unchanged in the past 60 days.
Let’s briefly review the company’s performance leading up to this announcement.
Trends Shaping ACB’s Fiscal Q2 Performance
Aurora Cannabis’ fiscal 2027 second-quarter results are expected to reflect the impact of recent strategic actions. In the fourth quarter of fiscal 2026, the company initiated its exit from certain markets within the lower-margin Canadian consumer segment, in order to reallocate resources toward evolving and more attractive global medical cannabis markets. In February 2026, Aurora Cannabis divested its lower-margin plant propagation business by selling its controlling stake in Bevo Agtech Inc.
In addition, Canadian medical cannabis revenues are likely to have declined following changes to the federal reimbursement program that took effect on April 1, 2026, lowering reimbursement rates by approximately 30%. Together, these factors might have weighed significantly on the company’s overall revenues in the fiscal second quarter.
On a positive note, international medical cannabis results likely have been driven by strong performance in Germany. Aurora Cannabis’ acquisition of Safari Flower Company, an established EU GMP-certified cannabis cultivator and manufacturer, was accretive to adjusted EBITDA in the fiscal first quarter and is expected to continue contributing positively in fiscal 2027.
The acquisition expands the company’s EU GMP capacity which can help meet the growing international demand for high-quality EU GMP products. EU GMP certification remains a key requirement for Aurora Cannabis to compete in international medical cannabis markets and pursue long-term profitable growth.
Aurora Cannabis’ largest and fastest-growing international market, Germany likely contributed significantly to the fiscal second-quarter revenues.The country’s rigorous GMP requirements are viewed as a competitive advantage, which has helped the company establish a strong reputation with wholesalers, distributors and pharmacists. Aurora Cannabis continues to hold leading market share by offering core and premium products while expanding value options amid rising competition and pricing pressure.
Further, the company’s strong commercial execution might have helped its performance in Poland. Recent increases in annual import limits, along with loyal patient base, also bode well for further growth in this highly regulated market.
In Australia, Aurora Cannabis’ strong market position might have supported the shift in sales mix toward core and premium products, reflecting growing demand from both prescribing physicians and patients for higher-tier options. The country’s broad product-format options might have helped Aurora Cannabis capitalize on its diverse portfolio beyond flower and oils.
The company might have also benefited from New Zealand, another highly regulated market, where patients continue to respond favorably to its expanding product assortment.
What Our Model Unveils for ACB
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see.
Earnings ESP: Aurora Cannabis has an Earnings ESP of 0.00% at present. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3 (Hold).
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company’s fiscal first-quarter EPS indicates an increase of 8.2% from the year-ago quarter’s figure.
Becton, Dickinson and Company (BDX - Free Report) , or BD, has an Earnings ESP of +0.21% and a Zacks Rank #2. The company will release its fourth-quarter fiscal 2026 results on Nov. 5.
BD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.94%. The Zacks Consensus Estimate for the company’s fiscal fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter’s figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.59% and a Zacks Rank #2. The company is slated to release third-quarter 2026 results on Nov. 2.
IDXX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for the company’s third-quarter EPS implies a jump of 9.1% from the year-ago quarter’s figure.
View the Zacks #1 Rank List
Image: Bigstock
ACB's Q2 Earnings on Deck: International Medical Cannabis in Focus
Key Takeaways
Aurora Cannabis Inc. (ACB - Free Report) is expected to report second-quarter fiscal 2027 results soon.
The renowned medical cannabis company posted earnings per share (EPS) of 4 cents in the last reported quarter, which surpassed the Zacks Consensus Estimate by 130.77%. The company’s earnings topped estimates in each of the trailing four quarters, the average surprise being 176.92%.
ACB’s Fiscal Q2 Estimates
For the fiscal second quarter, the Zacks Consensus Estimate for Aurora Cannabis’revenues is pegged at $52.5 million, indicating a 20.1% decrease from the year-ago reported figure.
The Zacks Consensus Estimate for the company’s fiscal second-quarter stands at a loss of 3 cents, in contrast to an EPS of 9 cents in the prior-year quarter. The estimate has remained unchanged in the past 60 days.
Let’s briefly review the company’s performance leading up to this announcement.
Trends Shaping ACB’s Fiscal Q2 Performance
Aurora Cannabis’ fiscal 2027 second-quarter results are expected to reflect the impact of recent strategic actions. In the fourth quarter of fiscal 2026, the company initiated its exit from certain markets within the lower-margin Canadian consumer segment, in order to reallocate resources toward evolving and more attractive global medical cannabis markets. In February 2026, Aurora Cannabis divested its lower-margin plant propagation business by selling its controlling stake in Bevo Agtech Inc.
In addition, Canadian medical cannabis revenues are likely to have declined following changes to the federal reimbursement program that took effect on April 1, 2026, lowering reimbursement rates by approximately 30%. Together, these factors might have weighed significantly on the company’s overall revenues in the fiscal second quarter.
Aurora Cannabis Inc. Price and EPS Surprise
Aurora Cannabis Inc. price-eps-surprise | Aurora Cannabis Inc. Quote
On a positive note, international medical cannabis results likely have been driven by strong performance in Germany. Aurora Cannabis’ acquisition of Safari Flower Company, an established EU GMP-certified cannabis cultivator and manufacturer, was accretive to adjusted EBITDA in the fiscal first quarter and is expected to continue contributing positively in fiscal 2027.
The acquisition expands the company’s EU GMP capacity which can help meet the growing international demand for high-quality EU GMP products. EU GMP certification remains a key requirement for Aurora Cannabis to compete in international medical cannabis markets and pursue long-term profitable growth.
Aurora Cannabis’ largest and fastest-growing international market, Germany likely contributed significantly to the fiscal second-quarter revenues.The country’s rigorous GMP requirements are viewed as a competitive advantage, which has helped the company establish a strong reputation with wholesalers, distributors and pharmacists. Aurora Cannabis continues to hold leading market share by offering core and premium products while expanding value options amid rising competition and pricing pressure.
Further, the company’s strong commercial execution might have helped its performance in Poland. Recent increases in annual import limits, along with loyal patient base, also bode well for further growth in this highly regulated market.
In Australia, Aurora Cannabis’ strong market position might have supported the shift in sales mix toward core and premium products, reflecting growing demand from both prescribing physicians and patients for higher-tier options. The country’s broad product-format options might have helped Aurora Cannabis capitalize on its diverse portfolio beyond flower and oils.
The company might have also benefited from New Zealand, another highly regulated market, where patients continue to respond favorably to its expanding product assortment.
What Our Model Unveils for ACB
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see.
Earnings ESP: Aurora Cannabis has an Earnings ESP of 0.00% at present. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3 (Hold).
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Phibro Animal Health (PAHC - Free Report) has an Earnings ESP of +2.10% and a Zacks Rank #1. The company is expected to release first-quarter fiscal 2027 results soon. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company’s fiscal first-quarter EPS indicates an increase of 8.2% from the year-ago quarter’s figure.
Becton, Dickinson and Company (BDX - Free Report) , or BD, has an Earnings ESP of +0.21% and a Zacks Rank #2. The company will release its fourth-quarter fiscal 2026 results on Nov. 5.
BD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.94%. The Zacks Consensus Estimate for the company’s fiscal fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter’s figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.59% and a Zacks Rank #2. The company is slated to release third-quarter 2026 results on Nov. 2.
IDXX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for the company’s third-quarter EPS implies a jump of 9.1% from the year-ago quarter’s figure.